Belsomra (Suvorexant) Safety Profile Differences in Black / African Ancestry Patients

Why Ethnicity Matters for Suvorexant Prescribing

Sleep health disparities affect Black Americans disproportionately. The CDC's Behavioral Risk Factor Surveillance System found that 46.3% of Black adults reported sleeping fewer than 7 hours per night, compared to 33.4% of white adults [1]. This gap means Black patients are more likely to receive prescriptions for insomnia pharmacotherapy, including suvorexant.

Pharmacogenomic Variation in CYP3A4

Suvorexant undergoes hepatic metabolism primarily through CYP3A4 [2]. Genetic polymorphisms in this enzyme vary by ancestry. The CYP3A4*20 allele, a loss-of-function variant, appears in approximately 1.1% of individuals with African ancestry but is virtually absent in European populations [3]. Carriers of this allele may metabolize suvorexant more slowly, leading to higher plasma concentrations and prolonged drug effect.

The Clinical Significance Gap

Population pharmacokinetic analyses submitted to the FDA did not identify race as a statistically significant covariate for suvorexant clearance [2]. This finding must be interpreted carefully. The Phase III program enrolled a relatively small proportion of Black participants. Subgroup sizes may have been underpowered to detect modest pharmacokinetic differences that become clinically relevant in individual patients, particularly those carrying rare CYP3A4 loss-of-function alleles.

Phase III Trial Data: What the Evidence Shows

The two registration trials for suvorexant (Study 006 and Study 028) enrolled over 3,000 participants combined and measured subjective and polysomnographic sleep outcomes over 3 months and 12 months, respectively [4]. Herring et al. Reported that suvorexant significantly improved subjective total sleep time (sTST) and wake after sleep onset (sWASO) across the pooled population.

Ethnicity-Stratified Subgroup Results

The FDA's Clinical Pharmacology and Biopharmaceutics Review documented that Black participants comprised roughly 10% of the Phase III population [2]. In subgroup analyses, the treatment effect on sTST and sWASO was directionally consistent with the overall population. No differential safety signals emerged in the Black subgroup for somnolence, suicidal ideation, sleep paralysis, or complex sleep behaviors.

Limitations of Available Data

A 10% representation in a trial of 3,000 translates to approximately 300 Black participants, split across dose groups and placebo. That sample size can confirm the absence of large safety differences. It cannot rule out a 2 to 3 percentage point increase in adverse event rates. The Endocrine Society's 2017 position statement on racial/ethnic diversity in clinical trials noted that "subgroup analyses are frequently underpowered and should be interpreted with caution when minority enrollment falls below 15 to 20% of the study population" [5].

CYP3A4 Pharmacogenomics and Suvorexant Exposure

CYP3A4 is responsible for approximately 50% of all drug metabolism in humans. Its genetic variability influences the pharmacokinetics of hundreds of medications, suvorexant included [6].

Key Alleles in African-Descent Populations

Several CYP3A4 alleles show differential frequency by ancestry. CYP3A41B (a promoter variant, rs2740574) is present in 53 to 78% of African Americans compared to 2 to 9% of European Americans [3]. Earlier studies suggested CYP3A41B reduced enzyme activity, but more recent data indicate its functional impact is modest and inconsistent across substrates.

CYP3A4*20 is a frameshift mutation that abolishes enzyme function entirely. Although rare (approximately 1.1% allele frequency in African Americans), a heterozygous carrier would have reduced CYP3A4 capacity [3]. For a drug like suvorexant with a 12-hour half-life, even a 20 to 30% reduction in clearance could extend next-morning sedation.

CYP3A4 Inhibitor Interactions: A Compounding Factor

The suvorexant prescribing information recommends a maximum dose of 5 mg when co-administered with moderate CYP3A4 inhibitors and contraindicates use with strong CYP3A4 inhibitors [2]. Black Americans have higher rates of HIV treatment with protease inhibitors (strong CYP3A4 inhibitors like ritonavir) and may use azole antifungals or diltiazem for comorbid conditions. These drug-drug interactions could compound any genetically reduced clearance.

PharmGKB lists suvorexant with CYP3A4 as a "major" metabolic pathway and flags the interaction risk as clinically actionable [7]. Clinicians prescribing suvorexant to patients already taking CYP3A4 inhibitors should start at the lowest available dose regardless of ancestry.

Sleep Disparities and Comorbidity Burden

Black Americans face a well-documented burden of sleep disorders that extends beyond insomnia prevalence.

Short Sleep and Cardiometabolic Risk

The Jackson Heart Study (N = 5,301 Black adults) found that short sleep duration (defined as fewer than 6 hours) was associated with a 1.6-fold increased risk of incident hypertension over 8 years of follow-up [8]. Untreated insomnia compounds existing cardiovascular risk, making effective pharmacotherapy clinically important in this population.

Obstructive Sleep Apnea Overlap

Black adults have a higher prevalence of obstructive sleep apnea (OSA) than white adults, with estimates ranging from 1.4 to 2.0 times higher depending on the cohort [9]. Suvorexant does not treat OSA and may theoretically worsen it by reducing arousal responses. The FDA label warns against use in patients with severe OSA unless adequately treated with CPAP [2]. Clinicians should screen for OSA before initiating suvorexant, a step that is especially relevant for Black patients given the higher baseline prevalence.

The Insomnia Treatment Gap

Despite higher rates of insomnia symptoms, Black Americans are less likely to receive a formal insomnia diagnosis and less likely to be referred for cognitive behavioral therapy for insomnia (CBT-I), the first-line treatment recommended by the American Academy of Sleep Medicine [10]. When pharmacotherapy is indicated, the choice of agent should account for individual risk factors, including metabolic genotype, comorbidities, and concurrent medications.

Dosing Recommendations for Black / African Ancestry Patients

The FDA-approved starting dose for suvorexant is 10 mg nightly, with an option to increase to 20 mg if the 10 mg dose is tolerated but insufficiently effective [2]. No race-based dose adjustment is recommended in the label.

When to Consider Lower Starting Doses

A 5 mg dose is available primarily for patients taking moderate CYP3A4 inhibitors. Clinicians may also consider starting at 5 mg for patients who report high sensitivity to sedating medications, have mild hepatic impairment, or are taking multiple CNS depressants. If a patient reports persistent next-day somnolence or grogginess at 10 mg, dose reduction rather than discontinuation is reasonable.

Monitoring for Next-Day Effects

Next-day somnolence was the most common adverse event in Phase III trials, reported in 7% of participants receiving suvorexant 20 mg vs. 3% on placebo [4]. The FDA's 2014 approval review specifically noted that "patients should be advised to use caution when driving or operating machinery the morning after taking suvorexant, particularly at the 20 mg dose" [2]. This guidance applies equally across all ancestry groups, but patients with reduced CYP3A4 activity may be at incrementally higher risk.

Titration Strategy

A practical approach: start at 10 mg for 7 to 14 nights. Assess both efficacy (subjective sleep onset latency, total sleep time) and tolerability (morning alertness, daytime functioning). If residual sedation occurs, reduce to 5 mg. If efficacy is inadequate and the drug is well tolerated, increase to 20 mg. Document the assessment at each step.

G6PD Deficiency: A Non-Issue for Suvorexant

Glucose-6-phosphate dehydrogenase (G6PD) deficiency affects approximately 10 to 14% of Black American males [11]. Certain drugs (primaquine, dapsone, rasburicase) can trigger hemolytic crises in G6PD-deficient individuals. Suvorexant does not cause oxidative stress to red blood cells and is not listed among drugs contraindicated or cautioned in G6PD deficiency. No hemolytic adverse events were reported in clinical trials [2]. G6PD status does not need to be checked before prescribing suvorexant.

Comparison with Other Insomnia Agents in Black Patients

Choosing among insomnia pharmacotherapies requires weighing efficacy, safety, and the pharmacogenomic profile of each option.

Suvorexant vs. Zolpidem

Zolpidem is metabolized by CYP3A4 and CYP2C9. The FDA reduced the recommended dose for women in 2013 due to sex-based pharmacokinetic differences but has not issued race-specific guidance [12]. Both drugs share CYP3A4 as the primary metabolic pathway, meaning the same pharmacogenomic considerations apply. Suvorexant's longer half-life (12 hours vs. 2 to 3 hours for zolpidem) may make next-day effects more pronounced in slow metabolizers.

Suvorexant vs. Lemborexant

Lemborexant (Dayvigo), the other approved DORA, is also metabolized by CYP3A4 but has a shorter half-life of approximately 17 to 19 hours at steady state [13]. Its Phase III program (SUNRISE-1 and SUNRISE-2) similarly had limited Black participant enrollment. Neither DORA has a clear pharmacogenomic advantage over the other in African-descent populations based on current data.

Suvorexant vs. Low-Dose Doxepin

Low-dose doxepin (Silenor, 3 to 6 mg) is metabolized primarily by CYP2D6 and CYP2C19 rather than CYP3A4 [14]. CYP2D6 poor-metabolizer status is less common in Black Americans (approximately 3 to 4%) than in white Americans (5 to 10%). For patients with known CYP3A4 loss-of-function variants, doxepin may offer a metabolic pathway with less variability.

What Prescribers Should Do Now

The American Academy of Sleep Medicine's 2017 clinical practice guideline for pharmacologic treatment of chronic insomnia recommended suvorexant as one of several options, noting that "the decision should be individualized based on patient characteristics, comorbidities, and drug properties" [10].

Practical Checklist

Screen for OSA before starting suvorexant, especially in Black patients given the higher OSA prevalence. Review the medication list for CYP3A4 inhibitors (azole antifungals, protease inhibitors, diltiazem, verapamil, clarithromycin). Start at 10 mg nightly; consider 5 mg if a moderate CYP3A4 inhibitor is present. Reassess at 7 to 14 days for morning sedation and efficacy. Pharmacogenomic testing for CYP3A4 is not routinely recommended but may be informative for patients with unexplained drug sensitivity across multiple CYP3A4 substrates.

Suvorexant 10 mg costs approximately $15 to $20 per tablet without insurance at retail pharmacies, though manufacturer savings programs and formulary placement vary [2]. Cost can be a barrier for uninsured or underinsured patients, a consideration that disproportionately affects Black Americans given insurance coverage disparities.